Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00534313 · ClinicalTrials.gov registry record · Phase 2
Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis
A Phase 2 study, sponsored by Bristol-Myers Squibb.
- Terminated
- Registry status
- Phase 2
- Development phase
- 191
- Enrollment target
NCT00534313 is a Phase 2 study that was terminated before completion, run by Bristol-Myers Squibb. The registered enrollment target is 191 participants.
The verdict
NCT00534313, a Phase 2 study, was terminated before completion, sponsored by Bristol-Myers Squibb.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 191 participants
- Enrollment target
Study Summary
The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockade compounds.
Interventions
- DRUG Placebo
- DRUG Abatacept
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 191 participants |
| Start Date | 2007-11 |
| Est. Completion | 2011-05 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00534313
The ClinicalTrials.gov registry entry for NCT00534313 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 191 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Bristol-Myers Squibb, which has 1,025 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00534313 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00534313 about?
NCT00534313 is a clinical study titled "Safety and Efficacy of Abatacept Versus Placebo in Participants With Psoriatic Arthritis". The purpose of this study is to determine an optimal abatacept dosing regimen for the treatment of active arthritis due to psoriatic arthritis in patients who have had a prior inadequate response to disease-modifying antirheumatic drugs, including methotrexate and tumor necrosis factor alpha-blockad...
What is the current status of trial NCT00534313?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 191 participants. The study started on 2007-11. Estimated completion is 2011-05.
What interventions are being tested in trial NCT00534313?
The interventions under investigation include: Placebo (DRUG), Abatacept (DRUG).
Who is sponsoring clinical trial NCT00534313?
This trial is sponsored by Bristol-Myers Squibb, which has 1,025 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.